Dr Jaks Pharma Private Limited
Founded in 2016 and headquartered in Telangana, India.
2016 | Hyderabad, Telangana (India) | Active
Dr Jaks Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 158.75%
- Profit Growth 243.97%
- Ebitda 1907.57%
- Net Worth 17.85%
- Total Assets 207.86%
About Dr Jaks Pharma
Dr Jaks Pharma Private Limited (DJPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 September 2016 (Eight years and four months 30 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Jogula and Masaiah Jogula serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24110TG2016PTC112257
- Company No.
112257
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Chemicals
Who are the key members and board of directors at Dr Jaks Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Jogula  | Director | 30-Sep-2016 | Current |
| Masaiah Jogula | Director | 30-Sep-2016 | Current |
Financial Performance of Dr Jaks Pharma.
Dr Jaks Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 158.75% increase. The company also saw a substantial improvement in profitability, with a 243.97% increase in profit. The company's net worth Soared by an impressive increase of 17.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Jaks Pharma?
Unlock access to Dr Jaks Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sree Bakthavastala Chits Private LimitedMasaiah Jogula is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Jaks Pharma?
Unlock and access historical data on people associated with Dr Jaks Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Jaks Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Jaks Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.